MENU
+Compare
RARE
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$35.37
Change
+$1.53 (+4.52%)
Capitalization
3.32B

RARE Ultragenyx Pharmaceutical Forecast, Technical & Fundamental Analysis

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company... Show more

Industry: #Biotechnology
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RARE with price predictions
Apr 01, 2025

RARE in upward trend: price may ascend as a result of having broken its lower Bollinger Band on March 31, 2025

RARE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where RARE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for RARE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RARE as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RARE turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RARE entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.453) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (5.467) is also within normal values, averaging (251.391).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RARE is expected to report earnings to rise 12.23% to -155 cents per share on May 01

Ultragenyx Pharmaceutical RARE Stock Earnings Reports
Q1'25
Est.
$-1.56
Q4'24
Missed
by $0.05
Q3'24
Beat
by $0.08
Q2'24
Beat
by $0.14
Q1'24
Missed
by $0.28
The last earnings report on February 13 showed earnings per share of -138 cents, missing the estimate of -134 cents. With 570.90K shares outstanding, the current market capitalization sits at 3.32B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Leveroni Court
Phone
+1 415 483-8800
Employees
1276
Web
https://www.ultragenyx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRWVX23.080.23
+1.01%
MFS Blended Research Growth Eq R6
APDYX22.230.19
+0.86%
Artisan Developing World Advisor
APDQX15.430.13
+0.85%
Artisan Mid Cap Value Advisor
RICBX55.750.29
+0.52%
American Funds Invmt Co of Amer R2
VYRDX15.55N/A
N/A
VY® Columbia Small Cap Value II R6

RARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+4.52%
VCYT - RARE
46%
Loosely correlated
+1.93%
CRNX - RARE
44%
Loosely correlated
+2.51%
RVMD - RARE
42%
Loosely correlated
+2.91%
DNLI - RARE
39%
Loosely correlated
+11.80%
ARWR - RARE
39%
Loosely correlated
+3.97%
More